Login / Signup

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.

Reinhard DummerKeith T FlahertyCaroline RobertAna M AranceJan Willem B de GrootClaus GarbeHelen J GogasRalf GutzmerIvana KrajsováGabriella LiszkayCarmen LoquaiMario MandalaDirk SchadendorfNaoya YamazakiAlessandra di PietroJean Cantey-KiserMichelle EdwardsPaolo Antonio Ascierto
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
V600-mutant melanoma.
Keyphrases
  • phase iii
  • open label
  • wild type
  • phase ii
  • clinical trial
  • phase ii study
  • skin cancer
  • study protocol
  • double blind
  • placebo controlled
  • basal cell carcinoma
  • randomized controlled trial